Novanta Inc. (Nasdaq: NOVT), a Boston-based technology partner to medical and industrial original equipment manufacturers, announced Tuesday it has entered into a definitive agreement to acquire Riverpoint Medical from private equity firm Arlington Capital Partners in a deal valued at up to $1.45 billion. The transaction includes $1.2 billion in upfront cash consideration at closing, expected in the third quarter of 2026, and a $250 million milestone payment scheduled for the first quarter of 2027, subject to customary regulatory approvals and closing conditions.
The acquisition is immediately accretive to Novanta’s revenue growth, adjusted gross margins, adjusted EBITDA margins, adjusted diluted earnings per share, and operating cash flows. Critically, it doubles Novanta’s recurring medical consumables revenue in a single transaction — a portfolio transformation that meaningfully reduces the business cyclicality that has historically characterized the company’s industrial revenue exposure.
What Riverpoint Medical Brings to the Table
Founded in 2008 and headquartered in Portland, Oregon, Riverpoint Medical is a developer, designer, and manufacturer of highly engineered minimally invasive surgical consumables and instruments. The company’s core competency is advanced surgical fiber technology — proprietary implants and constructs used across high-growth end markets including sports medicine, trauma, and cardiovascular surgery. Riverpoint operates as a private-label supplier to strategic OEM partners, manufacturing products that carry those partners’ brands rather than its own, embedding itself deeply into customer supply chains in a way that generates durable, recurring revenue relationships.
That business model is precisely what makes the acquisition strategically coherent for Novanta. Medical consumables consumed during surgical procedures are replaced with every case, creating a revenue stream that is predictable, recurring, and largely insulated from the capital equipment budget cycles that create volatility in Novanta’s industrial segment.
Riverpoint operates manufacturing facilities across North America and has invested in international production capacity, including a facility in Costa Rica’s Zona Franca Coyol free trade zone. Novanta has signaled a clear intention to accelerate Riverpoint’s European expansion by leveraging its existing international OEM customer relationships — creating a near-term revenue lever that organic growth alone could not have achieved as quickly.
The Minimally Invasive Surgery Tailwind
The strategic backdrop for this deal is straightforward. Minimally invasive surgery has been one of the most consistently high-growth segments in medical device markets for over a decade, driven by an aging global population, preference for shorter recovery times, reduced hospital stay costs, and continuous procedural innovation. The sports medicine and orthopedic segments in particular have seen sustained volume growth as active aging and sports participation rates support a durable patient pipeline.
For small and microcap investors tracking the medical device and surgical technology space, the Novanta-Riverpoint deal is a signal that strategic acquirers continue to assign premium valuations to companies with recurring revenue models, proprietary technology, and deep OEM integration in high-volume surgical end markets. Arlington Capital Partners built Riverpoint through targeted acquisitions, including the purchase of CP Medical in June 2024, before achieving a full exit to a public company buyer at a significant return.
The structure of the deal — with $250 million in contingent milestone consideration — reflects the forward growth expectations embedded in the transaction and aligns both parties around Riverpoint’s continued performance post-close.